{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:24:40Z","timestamp":1777868680077,"version":"3.51.4"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chang-Gung Research Program","award":["CMRPG3K0971"],"award-info":[{"award-number":["CMRPG3K0971"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/objectives: Current treatments for advanced hepatocellular carcinoma (HCC) are tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI). When HCC is resistant to TKI or ICI, subsequent available treatments are limited. Dendritic cells (DC) can activate antigen-specific cytotoxic T-cells and may be employed as a subsequent treatment when HCC is resistant to TKI or ICI treatments. Methods: Fifty advanced HCC patients with resistance to ICI or TKI treatment were invited to have autologous DC therapy. DCs were propagated from peripheral blood monocytes and pulsed with tumor lysate. All the patients received \u22653 courses of DC intravenously. For the outcome analysis, 17 patients who were resistant to TKI or other traditional treatments were grouped into A, and 33 patients who were resistant to ICI treatment were grouped into B. Results: For group A patients, the median (interquartile) progression-free and overall survivals were 6 (3\u201316.3) and 19 (8\u201324) months, respectively. The 1-, 2- and 3-year overall survivals after DC therapy were 58.2%, 21.8%, and 14.6%, respectively. For group B patients, the median (interquartile) progression-free and overall survivals were 5.0 (4\u20138) and 9 (5\u201314.5) months, respectively. The 1-, 2- and 3-year overall survivals after DC therapy were 27.6%, 8.6% and 4.3%, respectively. Taking together 50 patients, the objective response rate was 6.0% and disease control rate was 72.0%. Only three patients (6.0%) had grade I-II hepatitis. Conclusions: DC therapy is a safe treatment for advanced HCC patients. DC can serve as a subsequent therapy to extend the patients\u2019 lives when TKI or ICI treatments are ineffective as advanced HCC treatments.<\/jats:p>","DOI":"10.3390\/cancers18091433","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:47:28Z","timestamp":1777546048000},"page":"1433","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dendritic Cell Served as Salvage Therapy for Advanced Hepatocellular Carcinoma Resistant to Tyrosine Kinase or Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-1324","authenticated-orcid":false,"given":"Wei-Chen","family":"Lee","sequence":"first","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-8851","authenticated-orcid":false,"given":"Tsung-Han","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsien","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8830-3679","authenticated-orcid":false,"given":"Hao-Chien","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Chiao","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Fang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-8758","authenticated-orcid":false,"given":"Ting-Jung","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-2048","authenticated-orcid":false,"given":"Hong-Shiue","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Linkou Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.ejso.2015.05.024","article-title":"Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era","volume":"41","author":"Lee","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacifi c region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2021.02.001","article-title":"Resistance mechanisms to checkpoint inhibitors","volume":"69","author":"Weiss","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic Cell-Based Cancer Vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0167-5699(97)01030-X","article-title":"Dendritic cells hold promise for immunotherapy","volume":"18","author":"Girolomoni","year":"1997","journal-title":"Immunol. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.immunol.18.1.245","article-title":"Dendritic cells in cancer immunotherapy","volume":"18","author":"Fong","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic Cell-Based Immunotherapy: State of the Art and Beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/01.cji.0000171291.72039.e2","article-title":"Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic Cells-A Clinical Trial","volume":"28","author":"Lee","year":"2005","journal-title":"J. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jcyt.2018.06.002","article-title":"Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis","volume":"20","author":"Chen","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/JHC.S224938","article-title":"Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date","volume":"7","author":"Raybould","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Draube, A., Klein-Gonzalez, N., Mattheus, S., Brillant, C., Hellmich, M., Engert, A., and von Bergwelt-Baildon, M. (2011). Dendritic cell based tumor vaccination in prostate and renal cell cancer: A systematic review and meta-analysis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018801"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1328335","DOI":"10.1080\/2162402X.2017.1328335","article-title":"Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study","volume":"6","author":"Lee","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Tsai, C.H., Chen, Y.Y., Wang, C.C., Wang, J.H., Hung, C.H., and Kuo, Y.H. (2023). Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11298-z"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Giraud, J., Chalopin, D., Blanc, J.F., and Saleh, M. (2021). Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.655697"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1007\/s12072-024-10728-9","article-title":"Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy","volume":"18","author":"Lai","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2217\/imt-2021-0254","article-title":"Enhancement of dendritic cell immunotherapy by recalling antigens for hepatocellular carcinoma in mice","volume":"14","author":"Lee","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"117580","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh","year":"2020","journal-title":"Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mestrallet, G., Sone, K., and Bhardwaj, N. (2022). Strategies to overcome DC dysregulation in the tumor microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.980709"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1433\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:24:26Z","timestamp":1777551866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091433"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091433","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}